Cargando…

Vaccine-induced immune thrombotic thrombocytopenia after the BNT162b2 mRNA Covid-19 vaccine: A case study

Detalles Bibliográficos
Autores principales:	Rodríguez, Carmen, Pérez-Nieva, Alberto, Máiz, Luis, Meijón, María del Mar, Llamas, Pilar, Monreal, Manuel, Bikdeli, Behnood, Jiménez, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Letter to the Editors-in-Chief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8501513/ https://www.ncbi.nlm.nih.gov/pubmed/34649161 http://dx.doi.org/10.1016/j.thromres.2021.10.002

Ejemplares similares

Four cases of acquired hemophilia A following immunization with mRNA BNT162b2 SARS-CoV-2 vaccine
por: Leone, Maria Cristina, et al.
Publicado: (2022)

Vaccine-induced immune thrombocytopenia and thrombosis after mRNA-1273 booster vaccination
por: Langerak, T., et al.
Publicado: (2022)

Double high-dose immunoglobulin for ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia()
por: Huang, Ching-Tai, et al.
Publicado: (2021)

Vaccine-Induced Immune Thrombotic Thrombocytopenia following BNT162b2 mRNA COVID-19 Booster: A Case Report
por: Lin, Tzu-Chien, et al.
Publicado: (2023)

Cerebral venous thrombosis and thrombocytopenia post-COVID-19 vaccination
por: Franchini, Massimo, et al.
Publicado: (2021)

A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination
por: King, Eleanor R., et al.
Publicado: (2021)

Acquired thrombotic thrombocytopenic purpura after first vaccination dose of BNT162b2 mRNA COVID-19 vaccine
por: Ruhe, Johannes, et al.
Publicado: (2021)

Immune-Mediated Thrombotic Thrombocytopenic Purpura after BNT162b2 Vaccine
por: Güney, Tekin, et al.
Publicado: (2022)

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
por: Akiyama, Hiroaki, et al.
Publicado: (2021)

Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases
por: Rodríguez-Jiménez, Pedro, et al.
Publicado: (2021)

No evidence of increased rate of thrombotic recurrences in patients with history of venous thromboembolism after vaccination for COVID-19
por: Porfidia, Angelo, et al.
Publicado: (2022)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Heterogeneity of Vaccine-Induced Immune Thrombotic Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination and Safety of Second Vaccination with BNT162b2
por: Lindhoff-Last, Edelgard, et al.
Publicado: (2021)

Detection of anti-GPIbα autoantibodies in a case of immune thrombocytopenia following COVID-19 vaccination
por: Nakamura, Takayuki, et al.
Publicado: (2022)

Acquired Thrombotic Thrombocytopenic Purpura Following BNT162b2 mRNA Coronavirus Disease Vaccination in a Japanese Patient
por: Yoshida, Kikuaki, et al.
Publicado: (2021)

Potential Triggers for Thrombocytopenia and/or Hemorrhage by the BNT162b2 Vaccine, Pfizer-BioNTech
por: Okada, Yusuke, et al.
Publicado: (2021)

BNT162b2 mRNA Vaccine Interference with Co-Administration of Tdap Vaccine
por: Chilimuri, Sridhar, et al.
Publicado: (2021)

Safety and BNT162b2 mRNA COVID-19 vaccination
por: Joob, Beuy, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Thrombotic thrombocytopenic purpura: a new menace after COVID bnt162b2 vaccine
por: Waqar, Syed Hamza Bin, et al.
Publicado: (2021)

Pericarditis after administration of the BNT162b2 mRNA COVID-19 vaccine
por: Ramírez-García, Almudena, et al.
Publicado: (2021)

BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity
por: Vizcarra, Pilar, et al.
Publicado: (2021)

Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine
por: Saito, Kazuyuki, et al.
Publicado: (2021)

Circulating immune cells with megakaryocyte signature in response to COVID-19 mRNA vaccination
por: Kanaji, Taisuke, et al.
Publicado: (2022)

New onset of hypomegakaryocytic thrombocytopenia with the potential for progression to aplastic anemia after BNT162b2 mRNA COVID-19 vaccination
por: Kobayashi, Mirei, et al.
Publicado: (2023)

Effectiveness of the BNT162b2 mRNA Covid-19 vaccine in Spanish healthcare workers
por: Núñez López, Concepción, et al.
Publicado: (2023)

Effectiveness of the BNT162b2 mRNA Covid-19 vaccine in Spanish healthcare workers
por: Núñez López, Concepción, et al.
Publicado: (2023)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020)

BNT162b2 mRNA COVID-19 Vaccine: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Delayed large pruritic eruption to the BNT162b2 mRNA vaccine
por: Terashima, Takeshi
Publicado: (2021)

Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination
por: Gouda, Wesam, et al.
Publicado: (2022)

Central serous chorioretinopathy following the BNT162b2 mRNA vaccine
por: Hanhart, J., et al.
Publicado: (2022)

Addendum: Systems vaccinology of the BNT162b2 mRNA vaccine in humans
por: Arunachalam, Prabhu S., et al.
Publicado: (2023)

Thrombocytopenia in COVID-19 and vaccine-induced thrombotic thrombocytopenia
por: Geronikolou, Styliani A., et al.
Publicado: (2022)

Vaccine-induced immune thrombotic thrombocytopenia
por: Klok, Frederikus A, et al.
Publicado: (2022)

Perspectives on vaccine induced thrombotic thrombocytopenia
por: Dotan, Arad, et al.
Publicado: (2021)

Vaccine-induced immune thrombotic thrombocytopenia
por: Kanack, Adam J., et al.
Publicado: (2022)

Vaccine-induced immune thrombotic thrombocytopenia
por: Cines, Douglas B., et al.
Publicado: (2023)

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
por: Dagan, Noa, et al.
Publicado: (2021)

Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine
por: Niebel, Dennis, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f0ov486f9p34e3c7ut81qu49ca